| Original language | English (US) |
|---|---|
| Pages (from-to) | 177-178 |
| Number of pages | 2 |
| Journal | Alimentary Pharmacology and Therapeutics |
| Volume | 51 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2020 |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
- Pharmacology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Editorial : biochemical responses do not tell the whole story in primary biliary cholangitis. / Bowlus, Christopher L.; Levy, Cynthia.
In: Alimentary Pharmacology and Therapeutics, Vol. 51, No. 1, 01.01.2020, p. 177-178.Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Editorial
T2 - biochemical responses do not tell the whole story in primary biliary cholangitis
AU - Bowlus, Christopher L.
AU - Levy, Cynthia
N1 - Funding Information: Declaration of personal interests : Christopher L. Bowlus has served as a speaker, a consultant and an advisory board member for BiomX, Cymabay Therapeutics, Gilead Biosciences, GlaxoSmithKline, and Intercept Pharmaceuticals, and has received research funding from BiomX, Cymabay Therapeutics, Eli Lilly, Genkyotex, Gilead Biosciences, GlaxoSmithKline, Intercept Pharmaceuticals, NGM Biosciences, Novartis, Shire, Takeda, TARGET Pharmasolutions. Cynthia Levy has served as a consultand and advisory member board for Cymabay Therapeutics, GlaxoSmithKline, Cara Therapeutics, Flashlight, Shire and TARGET Pharmasolutions, and has received research funding from Cymabay Therapeutics, Eli Lilly, Genkyotex, Gilead Biosciences, GlaxoSmithKline, Intercept Pharmaceuticals, Novartis, Genfit, Shire, TARGET Pharmasolutions, Cara Therapeutics, Durect and High Tide. Funding Information: Declaration of personal interests: Christopher L. Bowlus has served as a speaker, a consultant and an advisory board member for BiomX, Cymabay Therapeutics, Gilead Biosciences, GlaxoSmithKline, and Intercept Pharmaceuticals, and has received research funding from BiomX, Cymabay Therapeutics, Eli Lilly, Genkyotex, Gilead Biosciences, GlaxoSmithKline, Intercept Pharmaceuticals, NGM Biosciences, Novartis, Shire, Takeda, TARGET Pharmasolutions. Cynthia Levy has served as a consultand and advisory member board for Cymabay Therapeutics, GlaxoSmithKline, Cara Therapeutics, Flashlight, Shire and TARGET Pharmasolutions, and has received research funding from Cymabay Therapeutics, Eli Lilly, Genkyotex, Gilead Biosciences, GlaxoSmithKline, Intercept Pharmaceuticals, Novartis, Genfit, Shire, TARGET Pharmasolutions, Cara Therapeutics, Durect and High Tide.
PY - 2020/1/1
Y1 - 2020/1/1
UR - http://www.scopus.com/inward/record.url?scp=85076840265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076840265&partnerID=8YFLogxK
U2 - 10.1111/apt.15576
DO - 10.1111/apt.15576
M3 - Editorial
C2 - 31850576
AN - SCOPUS:85076840265
VL - 51
SP - 177
EP - 178
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 1
ER -